139 related articles for article (PubMed ID: 2324584)
1. [Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences].
Fukushima T; Ueda T; Kamiya K; Yoshida W; Tsutani H; Uchida M; Nakamura T; Kagawa D; Domae N
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):126-31. PubMed ID: 2324584
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
3. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
[TBL] [Abstract][Full Text] [Related]
4. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
Castagnola C; Nozza A; Corso A; Bernasconi C
Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C).
Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Regazzi Bonora M; Pagnucco G; Orlandi E; Bernasconi P; Canevari A; Rondanelli R
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():101-3. PubMed ID: 2713552
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
Damon LE; Plunkett W; Linker CA
Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
[TBL] [Abstract][Full Text] [Related]
7. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of a case of childhood acute non-lymphocytic leukemia (ANLL) using high-dose cytosine arabinoside for intensification of early therapy].
Imashuku S; Nakajima T; Morimoto S; Hibi S; Todo S; Morioka Y; Sugimoto T
Gan To Kagaku Ryoho; 1987 Feb; 14(2):527-30. PubMed ID: 3813580
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
Urabe A; Mizoguchi H; Hoshino S; Nomura T; Dan K; Toyama K; Kimura M; Ogawa T; Yamaguchi H; Mutoh Y
Int J Hematol; 1991 Feb; 54(1):75-7. PubMed ID: 1954354
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
11. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
[TBL] [Abstract][Full Text] [Related]
13. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
15. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
Lin SF; Liu HW; Chen TP
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
[TBL] [Abstract][Full Text] [Related]
18. [Successful recovery of an acute myelogenous leukemia patient from a coma possibly due to leukoencephalopathy].
Doki N; Saito Y; Hatsumi N; Irisawa H; Sakura T; Miyawaki S
Rinsho Ketsueki; 2003 Nov; 44(11):1090-4. PubMed ID: 14689873
[TBL] [Abstract][Full Text] [Related]
19. [Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia].
Motomura S; Fujisawa S; Anzai S; Fujimaki K; Hattori M; Fukawa H; Okubo T
Rinsho Ketsueki; 1995 Aug; 36(8):762-7. PubMed ID: 7563610
[TBL] [Abstract][Full Text] [Related]
20. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
